HIV and asthma, is there an association?

Kynyk, Jessica; Parsons, Jonathan P.; Para, Michael F.; Koletar, Susan L.; Diaz, Philip T.; Mastronarde, John G.

doi:10.1016/j.rmed.2011.12.017

Cited by 16 publications

(4 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Amongst children and adolescents living with HIV, the history of rhinitis was estimated at 60% [ 19 ]. Asthma was also considered a disease of high incidence and prevalence among children and adolescents living with HIV, according to other studies [ 22 - 24 ]. Regarding skin manifestations of HIV infection, eczema has been reported as a rather frequent disease among adults and children [ 25 - 29 ].…”

Section: Discussionmentioning

confidence: 99%

Allergic diseases in subjects under 18 years living with HIV

Linhar

Traebert

Galato

et al. 2014

All Asth Clin Immun

View full text Add to dashboard Cite

BackgroundIn recent decades there has been an increase in the prevalence of allergic disease. Manifestations of these diseases have allegedly been observed in people living with Human Immunodeficiency Virus (HIV), however, few studies have been directed at patients under 18 years old. In this context, the aim of this study is to estimate the prevalence of allergic disease in patients under 18 years old, living with HIV, and to investigate the relationship between clinico-immunological characteristics of the HIV infection and atopy.MethodsThis is a cross-sectional epidemiological study involving patients under 18 years of age who were followed up by specialized HIV services in the Southern Region of the State of Santa Catarina, Brazil, from February to October 2012. Data collection tools included a questionnaire established by the International Study of Asthma and Allergy in Childhood (ISAAC), socio-demographic data, as well as laboratory test results obtained from the medical records. Blood samples were taken to measure total serum Immunoglobulin E (IgE) levels and a Radioallergosorbent Test (RAST) for the main aeroallergens. Analysis was performed using Student’s t test, chi-squared, Fisher’s exact and Mann–Whitney tests, wherever indicated, with p < 0.05 value considered significant.Results29 individuals were evaluated. The prevalence of symptoms of allergic disease was 65.5% (95% CI 56.1-74.8), the most frequent being rhinitis 44.8% (95% CI 35.0-54.5), followed by asthma 37.9% (95% CI 28.3-47.4) and eczema 27.6% (95% CI 18.8-36.3). RAST was positive in 20.7% of the individuals. There was no significant difference in terms of total serum IgE between individuals with and without symptoms of allergic disease. Nevertheless, a high frequency of raised levels of total serum IgE (40.7%) and an association between raised IgE and clinical staging of disease were observed. A further association between CD8+ cell count and prevalence of symptomatic allergic disease (p = 0.014) was observed.ConclusionThere was a high prevalence of reported allergic disease, as well as a high frequency of raised levels of total serum IgE. The association between CD8+ cell count and the prevalence of symptomatic allergic disease corroborates studies that demonstrated the role of such cells in the development of allergic disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Allergic diseases in subjects under 18 years living with HIV

Linhar

Traebert

Galato

et al. 2014

All Asth Clin Immun

View full text Add to dashboard Cite

show abstract

“…Elevated serum IgE levels in HIV infection were recognized early in the AIDS epidemic, [81][82][83] but the relationship between these levels and asthma in HIV infection has not been extensively studied. In the study by Poirier and colleagues, more HIV-infected men had elevated total serum IgE levels compared with a control population (38% [95% CI: [32][33][34][35][36][37][38][39][40][41][42][43][44] vs. 26% [95% CI: [21][22][23][24][25][26][27][28][29][30][31]; no p-value provided).…”

Section: Hiv Infection and Markers Of Atopymentioning

confidence: 99%

Obstructive Lung Diseases in HIV: A Clinical Review and Identification of Key Future Research Needs

Drummond

Kunisaki

Huang

2016

Semin Respir Crit Care Med

View full text Add to dashboard Cite

HIV infection has shifted from what was once a disease directly impacting short-term mortality to what is now a chronic illness controllable in the era of effective combination antiretroviral therapy (ART). In this setting, life expectancy for HIV-infected individual is nearly comparable to that of individuals without HIV. Subsequent to this increase in life expectancy, there has been recognition of increased multimorbidity among HIV-infected persons, with prevalence of comorbid chronic illnesses now approaching 65%. Obstructive lung diseases, including chronic obstructive pulmonary disease (COPD) and asthma, are prevalent conditions associated with substantial morbidity and mortality in the United States. There is overlap in risk factors for HIV acquisition and chronic lung diseases, including lower socioeconomic status and the use of tobacco and illicit drugs. Objectives of this review are to (1) summarize the current state of knowledge regarding COPD and asthma among HIV-infected persons, (2) highlight implications for clinicians caring for patients with these combined comorbidities, and (3) identify key research initiatives to reduce the burden of obstructive lung diseases among HIV-infected persons.

show abstract

“…Recent cohort studies have demonstrated a rise in asthma incidence following antiretroviral therapy (ART) in US children living with HIV [1][2][3], possibly due to immune reconstitution [2]. As the extent of immune reconstitution can be affected by the pre-ART CD4 level, we assessed new onset asthma in a randomized study of children who initiated ART at different CD4 levels in the Pediatric Randomized Early versus Deferred Initiation in Cambodia and Thailand study (The PREDICT study) [4].…”

mentioning

confidence: 99%

“…inhaled budesonide, unspecified oral/inhaled bronchodilator, and salbutamol + budesonide) (12.5%). Median (IQR) durations of medications use were 16 (10-41) days for salbutamol, 7 [5][6][7][8] days for terbutaline, 167 (34-427) days for budesonide, and 5 [2][3][4][5][6] days for bronchodilator with no differences between arms (all p N 0.2).…”

mentioning

confidence: 99%